[go: up one dir, main page]

ES2061423T1 - Entrega de agentes de contraste con rayos x usando endocitosis interpuesta receptora - Google Patents

Entrega de agentes de contraste con rayos x usando endocitosis interpuesta receptora

Info

Publication number
ES2061423T1
ES2061423T1 ES92910570T ES92910570T ES2061423T1 ES 2061423 T1 ES2061423 T1 ES 2061423T1 ES 92910570 T ES92910570 T ES 92910570T ES 92910570 T ES92910570 T ES 92910570T ES 2061423 T1 ES2061423 T1 ES 2061423T1
Authority
ES
Spain
Prior art keywords
endocytosis
receiving
organ
ray
interposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES92910570T
Other languages
English (en)
Inventor
Lee Josephson
Chu Jung
Stephen Palmacci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharmaceuticals Inc
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Publication of ES2061423T1 publication Critical patent/ES2061423T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1808—Catalysts containing secondary or tertiary amines or salts thereof having alkylene polyamine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1816—Catalysts containing secondary or tertiary amines or salts thereof having carbocyclic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1825—Catalysts containing secondary or tertiary amines or salts thereof having hydroxy or primary amino groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/20—Heterocyclic amines; Salts thereof
    • C08G18/2009—Heterocyclic amines; Salts thereof containing one heterocyclic ring
    • C08G18/2036—Heterocyclic amines; Salts thereof containing one heterocyclic ring having at least three nitrogen atoms in the ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/24—Catalysts containing metal compounds of tin
    • C08G18/244—Catalysts containing metal compounds of tin tin salts of carboxylic acids
    • C08G18/246—Catalysts containing metal compounds of tin tin salts of carboxylic acids containing also tin-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/26—Catalysts containing metal compounds of lead
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
    • C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
    • C08J9/14—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
    • C08J9/143—Halogen containing compounds
    • C08J9/144—Halogen containing compounds containing carbon, halogen and hydrogen only
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00—Manufacture of cellular products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
    • C08J2375/04—Polyurethanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO DE LLEVAR UN AGENTE DE CONTRASTE DE RAYOS X A UNA POBLACION ESPECIFICA DE CELULAS U ORGANO. ESTO PUEDE LLEVARSE A CABO MEDIANTE LA FORMACION DE UN COMPLEJO DE UNA ETIQUETA OPACA A LAS RADIACIONES, CON UN SACARIDO CAPAZ DE INTERACTUAR CON UN RECEPTOR DE CELULAS. EL COMPLEJO RESULTANTE PUEDE INTERPONERSE ENTONCES DENTRO DE LA POBLACION ESPECIFICA DE CELULAS U ORGANO MEDIANTE ENDOCITOSIS INTERPUESTA RECEPTORA. EN UNA VERSION DE LA INVENCION, LA ETIQUETA OPACA A LAS RADIACIONES PUEDE INCLUIR UN COMPUESTO QUE CONTENGA YODO Y EL SACARIDO PUEDE INCLUIR ARABINOGALACTANO, GALACTANO, O DERIVADOS DE LOS MISMOS. LA INVENCION PROPORCIONA UN METODO PARA DETERMINAR LA VIABILIDAD METABOLICA O ESTADO DE ENFERMEDAD DE LAS CELULAS BLANCO U ORGANO MEDIANTE LA VISUALIZACION DE LA AMPLITUD, MODO DE CAPTACION Y EXCRECION DEL AGENTE DE CONTRASTE POR RAYOS X VISUALIZADOS MEDIANTE RAYOS X O TOMOGRAFIA DE ORDENADOR.
ES92910570T 1991-04-02 1992-03-18 Entrega de agentes de contraste con rayos x usando endocitosis interpuesta receptora Pending ES2061423T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/679,526 US5141739A (en) 1986-07-03 1991-04-02 Delivery of x-ray contrast agents using receptor mediated endocytosis

Publications (1)

Publication Number Publication Date
ES2061423T1 true ES2061423T1 (es) 1994-12-16

Family

ID=24727269

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910570T Pending ES2061423T1 (es) 1991-04-02 1992-03-18 Entrega de agentes de contraste con rayos x usando endocitosis interpuesta receptora

Country Status (8)

Country Link
US (1) US5141739A (es)
EP (1) EP0578765A1 (es)
JP (1) JPH06506230A (es)
CA (1) CA2105068A1 (es)
DE (1) DE578765T1 (es)
ES (1) ES2061423T1 (es)
GR (1) GR940300022T1 (es)
WO (1) WO1992017216A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
US5342605A (en) * 1992-05-01 1994-08-30 Sterling Winthrop Inc. Polymeric X-ray compositions containing iodinated polymeric beads
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
JPH08501097A (ja) * 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336923A (en) * 1992-12-31 1994-08-09 Honeywell, Inc. Varactor diode having a stepped capacitance-voltage profile
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
DE19731591C2 (de) * 1997-07-17 1999-09-16 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylgruppenhaltige Trijodaromaten und ihre Verwendung in der Tumortherapie und interventionellen Radiologie
US6245316B1 (en) 1997-10-08 2001-06-12 David Platt Enhancement of delivery of radioimaging and radioprotective agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6751290B2 (en) 1998-09-08 2004-06-15 Veritas Pharmaceuticals, Inc. Radiographic assessment of tissue after exposure to a compound
US6723746B2 (en) 1998-09-08 2004-04-20 Veritas Pharmaceuticals, Inc. Functional radiographic imaging methods and agents
US6226352B1 (en) * 1998-09-08 2001-05-01 Veritas Pharmaceuticals, Inc. System and method for radiographic imaging of tissue
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
FR2802817B1 (fr) * 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US7664543B2 (en) * 2001-04-26 2010-02-16 Analogic Corporation CT scanner for and method of imaging a preselected portion of the lower abdomen region of a patient
WO2002100444A1 (en) * 2001-06-08 2002-12-19 Biosphere Medical Inc. Colloidal metal labelled microparticles, their production and use
US20050255175A1 (en) * 2004-05-17 2005-11-17 Burgess W P Method for protecting nephron against injury caused by disruption of a chemical environment in the kidneys
US20050255176A1 (en) * 2004-05-17 2005-11-17 Burgess W P Method for attenuating free radical formation resulting from bodily insult
US7019035B2 (en) * 2004-05-17 2006-03-28 Md Scientific Llc Method for attenuating free radical formation resulting from bodily insult
US7625586B2 (en) * 2004-10-28 2009-12-01 Md Scientific, Llc Method for mitigating injury to a kidney resulting from an ischemic event
KR100695744B1 (ko) 2005-05-03 2007-03-19 한국원자력연구소 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제
CN1966088B (zh) * 2006-11-16 2010-09-29 中国科学院长春应用化学研究所 阿拉伯半乳聚糖为载体的磁共振成像造影剂
US8440168B2 (en) * 2008-03-24 2013-05-14 The Board Of Regents Of The University Of Texas System Image-guided therapy of myocardial disease: composition, manufacturing and applications
WO2011021175A2 (en) 2009-08-18 2011-02-24 Ben Gurion University Of The Negev Research And Development Authority System and method for analyzing imaging data
US9827265B1 (en) 2012-04-06 2017-11-28 Md Scientific, Llc Method for attenuating free radical formation resulting from a bodily insult
KR20160032000A (ko) 2013-03-15 2016-03-23 매튜 알. 드레허 이미지화 가능한 색전성 마이크로스피어
CN112481217A (zh) 2016-09-01 2021-03-12 嵌合体生物工程公司 Gold优化的car t-细胞

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6024559D0 (pt) * 1959-12-08 1973-05-31 Nyegaard & Co As Processo para preparacao de novos derivados de acido 3 5-diamino-2 4 6-triiodo benzoico ou semi sais nao toxicos bem como de agentes ou meios de contraste para raios x baseados nos mesmos
IT1053508B (it) * 1970-07-06 1981-10-10 Searle & Co Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4038379A (en) * 1976-03-24 1977-07-26 Nikolai Petrovich Elinov Composition for roentgenoscopy of the gastrointestinal tract containing a polysaccharide stabilizer
US4243653A (en) * 1979-04-27 1981-01-06 The Regents Of The University Of California Non-ionic polyiodo sugar substituted anilines
US4431626A (en) * 1981-05-27 1984-02-14 The Regents Of The University Of California Tc-99m Labeled carrier for imaging
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US4396598A (en) * 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
CA1224003A (en) * 1984-04-24 1987-07-14 Robert S. Molday Colloidal sized metal-polysaccharide particles
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
EP0381742B1 (en) * 1988-08-04 1996-06-19 Advanced Magnetics Incorporated Receptor mediated endocytosis type mri contrast agents
JPH04501560A (ja) * 1988-08-24 1992-03-19 ザ ユニバーシティ オブ コネチカット 磁気共鳴断層撮影の能力向上に役立つ担体システム並びに方法
EP0361960A3 (en) * 1988-09-29 1992-01-02 RANNEY, David F. Methods and compositions for magnetic resonance imaging
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
GB8919929D0 (en) * 1989-09-04 1989-10-18 Nycomed As Compositions

Also Published As

Publication number Publication date
EP0578765A1 (en) 1994-01-19
CA2105068A1 (en) 1992-10-03
GR940300022T1 (en) 1994-04-29
US5141739A (en) 1992-08-25
JPH06506230A (ja) 1994-07-14
DE578765T1 (de) 1994-05-26
WO1992017216A1 (en) 1992-10-15

Similar Documents

Publication Publication Date Title
ES2061423T1 (es) Entrega de agentes de contraste con rayos x usando endocitosis interpuesta receptora
Young et al. A flying-spot microscope
IT8019099A0 (it) Procedimento di sterilizzazione mediante l'uso di una soluzione di acqua ossigenata irradiata con radiazione ultravioletta
DE59102631D1 (de) Implantat zum Aufbau von Knochengewebe.
DK507183D0 (da) Bifunktionelt chelateringsmiddel
IT1116517B (it) Alcool benzilico sostituito otticamente attivo e procedimento per la sua produzione
DE69113422D1 (de) Kathodenstrahlröhrenanzeige.
FR2440183A1 (fr) Endoscope
DE3584704D1 (de) Kathodenstrahlroehrensichtgeraet.
DE3884570D1 (de) Roentgenstrahl-bildverstaerkerroehre.
Byalko Focusing of Radiation by a Gravitational Field.
ES8707296A1 (es) Un metodo para producir anticuerpos monoclonales humanos
ES2074692T3 (es) Estanteria metalica.
Mariner Extra-Corticle Membranes and Layers of the Wool Fibre
KR900010893A (ko) 보강형 음극선관
ES353089A1 (es) Dispositivo de grada.
Watson et al. 4U 1624-49
ES8608774A1 (es) Dispositivo perfeccionado de seguridad para apero agricola, que trabaja a gran profundidad
Waris Psychology, USA, current trends: implications for the Muslim world
Dower et al. Circinus X-1
JPS5396756A (en) Picture tube unit
LI Sacroiliac Syndrom
Ubertini et al. Hard X-ray observation of the supernova 1987A.
Faulkingham page, Acknowledgements, Table of contents, and List of tables and figures
CUI et al. Protective effect of?-scretase substrate-base peptide on cellular model of Alzheimer's disease